GlaxoSmithKline Vaccines, Wavre, Belgium.
Vaccine. 2013 Mar 25;31(13):1759-64. doi: 10.1016/j.vaccine.2013.01.002. Epub 2013 Jan 10.
The primary objective of this investigation was to assess whether the AS04-adjuvanted herpes simplex virus (HSV) glycoprotein D candidate prophylactic vaccine against genital herpes disease increases the risk of spontaneous abortion associated with pregnancy conceived within the vaccination exposure window (vaccine dose received within the period starting 60 days before and ending 20 weeks post-conception day). We performed a meta-analysis of studies designed as part of the clinical development program for this vaccine, to examine the relative risk of abortion (spontaneous or elective) associated with unintended vaccination exposure during pregnancy. Nineteen studies, completed before September 2010, were eligible; 5 matched the inclusion criteria for this analysis (presence of a control arm and at least one adverse pregnancy outcome reported). All vaccinated women (N=19,727) were included, of whom 660 reported a pregnancy during the study period. Overall, 13.3% of pregnancies in the HSV vaccine group and 11.0% in the control group resulted in spontaneous abortion; 24.2% and 20.0% resulted in elective abortion. Among 180 women with a first pregnancy conceived in the vaccination exposure window, 16.7% (HSV vaccine) and 9.5% (control) had a spontaneous abortion and 38.5% and 33.3%, elective abortion. The relative risk for spontaneous abortion associated with vaccine exposure during the risk period for abortion in the course of pregnancy was 1.7 (95% CI: 0.7-4.6). For all women receiving HSV vaccine, this relative risk was 1.3 (95% CI: 0.8-2.1). The corresponding relative risks for elective abortion were 1.2 (95% CI: 0.7-2.0) and 1.3 (95% CI: 0.9-1.8). There was no apparent relationship to dosing and no difference between groups in gestational age at the time of spontaneous or elective abortion. In conclusion there is no statistical evidence that the investigational HSV vaccine increased the risk of spontaneous or elective abortion.
本研究的主要目的是评估 AS04 佐剂的单纯疱疹病毒(HSV)糖蛋白 D 候选预防性疫苗是否会增加生殖器疱疹疾病的风险,这种风险与妊娠期间疫苗接种暴露窗口(受孕前 60 天至受孕后 20 周期间接受疫苗剂量)相关的自发性流产有关。我们对作为该疫苗临床开发计划一部分设计的研究进行了荟萃分析,以检查与妊娠期间意外疫苗接种暴露相关的流产(自然或人工)的相对风险。在 2010 年 9 月之前完成的 19 项研究符合本分析的纳入标准(存在对照组和至少报告了一个不良妊娠结局)。所有接种疫苗的女性(N=19727)均包括在内,其中 660 名在研究期间报告怀孕。总体而言,HSV 疫苗组中 13.3%的妊娠和对照组中 11.0%的妊娠导致自然流产;24.2%和 20.0%导致人工流产。在 180 名在疫苗接种暴露窗口内首次怀孕的女性中,16.7%(HSV 疫苗)和 9.5%(对照组)发生自然流产,38.5%和 33.3%发生人工流产。在妊娠流产风险期间疫苗暴露与自然流产相关的相对风险为 1.7(95%CI:0.7-4.6)。对于所有接受 HSV 疫苗的女性,这种相对风险为 1.3(95%CI:0.8-2.1)。人工流产的相应相对风险分别为 1.2(95%CI:0.7-2.0)和 1.3(95%CI:0.9-1.8)。剂量之间没有明显的关系,并且两组之间在自然或人工流产时的孕龄没有差异。总之,没有统计学证据表明研究性 HSV 疫苗增加了自然或人工流产的风险。